DUBLIN--(BUSINESS WIRE)--The "Creatinine Measurement Market to 2027 - Global Analysis and Forecasts by Product; Type; Sample Type; End-User, and Country" report has been added to ResearchAndMarkets.com's offering.
The creatinine measurement market was valued at US$ 384.69 million in 2019 and is projected to reach US$ 705.96 million by 2027; it is expected to grow at a CAGR of 8.0% from 2020 to 2027.
Factors driving the creatinine measurement market are increasing prevalence of chronic kidney disorders (CKD) and growing prevalence of CKD among the geriatric population. However, a gradual shift toward novel biomarkers is among the major factor restraining the market growth.
There is the growing prevalence of chronic kidney diseases. According to the American Society of Nephrology (ASN), several ongoing recent advancements in molecular diagnostics are supporting the management of patients suffering from kidney-related disorders. Developments in the fields such as nucleic acid amplification and detection, proteomics, genomic analysis, and metabolomics have enhanced several molecular diagnostic assays. Further, the measurement of creatinine concentration in serum or plasma is a widely used procedure in clinical chemistry to assess the functioning of kidneys.
There are different levels of CKD, and based on these stages, the creatinine levels can provide a comprehensive analysis of kidneys. Creatinine markers are used to determine the glomerular filtration rate, an essential parameter for diagnosing chronic kidney disease. Owing to its efficiency in the analysis of kidney function, Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommended the use of creatinine measurement for kidney screening in 2012. Therefore, increasing chronic kidney disorders, coupled with benefits of creatinine measurement to understand the condition of kidneys, is likely to boost the demand for creatinine measurement devices during the forecast period.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the creatinine measurement market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global creatinine measurement market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Market Dynamics
Drivers
- Increasing Prevalence of Chronic Kidney Disorders
- Growing Geriatric Population
Restraints
- Shift Toward Novel Biomarkers
Opportunities
- Emerging Markets in Developing Countries
Trends
- Point-of-Care Renal Functioning Testing
Companies Mentioned
- Siemens Healthcare Gmbh
- Abbott
- Cayman Chemical
- Thermo Fisher Scientific Inc.
- Fujifilm Wako Pure Chemical Corporation
- Randox Laboratories Ltd
- F. Hoffmann-La Roche Ltd
- Danaher (Beckman Coulter)
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Maccura Biotechnology Co., Ltd.
- Diazyme Laboratories, Inc
- Dialab Gmbh
- Beijing Jiuqiang Biotechnology Co., Ltd.
- Beijing Leadman Biochemistry
- Shanghai Fosun Pharmaceutical Group Co., Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/3ie2jd
